Recently, the results of the 12th batch of National Organized Drug Centralized Procurement (NODCP) were officially announced. Zhejiang CDMO Pharmaceutical, a wholly-owned subsidiary of Hangzhou Bio-Sincerity Pharma-Tech (Stock Code: 301096.SZ), has successfully had 5 product varieties selected for the procurement list, leveraging its robust quality management system, large-scale high-end manufacturing capacity, and reliable supply chain assurance. Among them, 1 variety is independently held by Zhejiang CDMO Pharmaceutical, and 4 varieties are manufactured under contract (CDMO cooperation model). This achievement not only represents a high-level recognition of the exceptional drug R&D and high-standard manufacturing capabilities of Bio-Sincerity Pharma-Tech and Zhejiang CDMO Pharmaceutical, but also marks a solid step forward for the company in actively responding to national healthcare reform policies and serving clinical medication needs.

（Factory of Zhejiang CDMO Pharmaceutical）

The National Organized Drug Centralized Procurement is a major initiative to deepen the reform of the medical and healthcare system and ensure that high-quality drugs benefit a broad patient population. The centralized procurement policy is guided by the core principles of "quality first, reasonable pricing, and supply assurance," aiming to eliminate inflated margins in the distribution chain and guide pharmaceutical enterprises back to their core focus on technological innovation and efficient production. For Zhejiang CDMO Pharmaceutical, the successful selection of 5 product varieties in this national centralized procurement is both a vivid manifestation of the company's social responsibility of "making good medicines more accessible" and an important example of how Bio-Sincerity Pharma-Tech's integrated "R&D + Manufacturing" strategy delivers tangible results at the industry level. Through the scale effects of the centralized procurement platform and stable capacity utilization, Zhejiang CDMO Pharmaceutical can not only help its partners expand market coverage, but also significantly enhance the accessibility and affordability of high-quality drugs in clinical practice.

The product varieties selected this time by Zhejiang CDMO Pharmaceutical are diverse in range and significant in clinical value, precisely addressing China's enormous needs in chronic disease management and specialized clinical care. In the fields of gynecology and assisted reproduction, Dydrogesterone Tablets manufactured by Zhejiang CDMO Pharmaceutical under contract (covering three partners: Zhejiang Gaozhi Pharmaceutical Technology, Beijing Jinchengtaier Pharmaceutical, and Guilin Langke Pharmaceutical) were successfully selected. This drug plays an irreplaceable role in treating uterine bleeding, dysmenorrhea, endometriosis, threatened abortion caused by endogenous progesterone deficiency, and luteal phase support in assisted reproductive technology. In the area of endocrine and metabolic diseases, Sitagliptin and Metformin Hydrochloride Sustained-Release Tablets independently held by Zhejiang CDMO Pharmaceutical and Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets manufactured under contract (covering two partners: Shandong Qidu Pharmaceutical and TZADA) were both selected. As highly effective combination preparations for the treatment of type 2 diabetes, they can significantly improve patient medication adherence and glycemic control rates. In the fields of cardiovascular/cerebrovascular diseases and antithrombotic therapy, Pentoxifylline Sustained-Release Tablets manufactured under contract (covering partner Hangzhou Fu'ou Pharmaceutical Technology, used to improve cerebral circulation disorders after ischemic stroke and peripheral vascular diseases) and Indobufen Tablets (covering two partners: Hunan Shangzhonghe Biomedicine and Zhejiang Bio-diamond Pharmaceutical Technology, used for ischemic cardiovascular and cerebrovascular lesions and antithrombotic prevention) were also successfully awarded. The high-standard selection of these varieties will significantly reduce the long-term medication burden for patients with relevant chronic and specialized diseases, providing guaranteed clinical efficacy and important social benefits.

As the core platform for Bio-Sincerity Pharma-Tech's CDMO industrialization, Zhejiang CDMO Pharmaceutical was established in 2019 and is located in the Health Biotechnology Industrial Park of Jinhua City, Zhejiang Province, covering an area of 380 mu (approximately 253,000 square meters). It serves as the core base for Bio-Sincerity Pharma-Tech to build a high-quality integrated R&D and manufacturing ecosystem. The company has built 140,000 square meters of GMP-compliant pharmaceutical production facilities and supporting laboratories, equipped with 55 advanced formulation production lines covering tablets, granules, capsules, liniments, eye drops, large/small-volume injections, inhalation formulations (including hormone-based), topical gels/ointments/creams, oral solutions/suspensions, and more, of which 31 have passed GMP inspection. In terms of source supply assurance, Zhejiang CDMO Pharmaceutical possesses over 200 proprietary raw materials and intermediates; 76 APIs have been registered and filed with the CDE, of which 56 have been approved for marketing, and 37 have passed GMP on-site inspection and been publicly announced. Furthermore, 3 products — Minoxidil, Amorolfine Hydrochloride, and Acetylcysteine — have been granted EU CEP certificates, and the factory has also obtained the Japan AFM certificate. The rigorous quality system and comprehensive API-to-formulation integrated industrial chain provide Zhejiang CDMO Pharmaceutical with a rock-solid foundation of quality and capacity assurance for undertaking large-scale national centralized procurement orders.

Looking ahead, Bio-Sincerity Pharma-Tech and Zhejiang CDMO Pharmaceutical will continue to position themselves at the forefront of pharmaceutical technology, uphold the spirit of medical professionalism and quality commitment, and strictly control the entire process of production, testing, and supply of centralized procurement drugs in accordance with national regulations, ensuring that every batch of drugs is safe, effective, and of controllable quality. At the same time, the company will continue to deepen strategic cooperation with outstanding domestic and international pharmaceutical enterprises, continuously deliver high-quality R&D and manufacturing services, ensure that the fruits of technological innovation benefit a broad patient population, and contribute to the building of a Healthy China.